582.24

1.31% 7.86

Thermo Fisher Scientific Inc (TMO)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt TMO? Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

$574.38

Offen:

$576

24-Stunden-Volumen:

120.85K

Relative Volume:

0.05

Marktkapitalisierung:

$216.35B

Einnahmen:

$45.20B

Nettoeinkommen (Verlust:

$6.87B

KGV:

32.01

EPS:

18.1888

Netto-Cashflow:

$6.75B

1W Leistung:

+4.00%

1M Leistung:

+11.17%

6M Leistung:

+2.08%

1J Leistung:

+25.68%

1-Tages-Spanne:

$575.16

$583.48

1-Wochen-Bereich:

$560.42

$588.56

52-Wochen-Spanne:

$435.27

$643.99

Thermo Fisher Scientific Inc Stock (TMO) Company Profile

Firmenname

Thermo Fisher Scientific Inc

Sektor

Healthcare (1085)

Branche

Diagnostics & Research (49)

Telefon

(781) 622-1000

Adresse

168 THIRD AVENUE, WALTHAM, MA

Mitarbeiter

125,000

Twitter

@thermofisher

Nächster Verdiensttermin

2026-07-23

Neueste SEC-Einreichungen

TMO's Discussions on Twitter

Compare TMO vs DHR, IDXX, A, IQV

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TMO Thermo Fisher Scientific Inc	582.18	207.93B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	198.84	138.14B	24.78B	3.68B	5.29B	5.1743
IDXX Idexx Laboratories Inc	576.75	43.87B	4.45B	1.10B	1.06B	13.59
A Agilent Technologies Inc	139.28	38.94B	7.23B	1.41B	1.09B	4.979
IQV Iqvia Holdings Inc	233.00	35.59B	16.63B	1.39B	2.12B	8.0674

Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-27	Eingeleitet	DZ Bank	Buy
2025-12-11	Hochstufung	Citigroup	Neutral → Buy
2025-12-09	Eingeleitet	Goldman	Buy
2025-12-08	Hochstufung	KeyBanc Capital Markets	Sector Weight → Overweight
2025-12-02	Fortgesetzt	Morgan Stanley	Overweight
2025-12-01	Hochstufung	HSBC Securities	Hold → Buy
2025-09-11	Hochstufung	Barclays	Equal Weight → Overweight
2025-08-19	Eingeleitet	William Blair	Outperform
2025-07-24	Herabstufung	HSBC Securities	Buy → Hold
2025-07-11	Hochstufung	Scotiabank	Sector Perform → Sector Outperform
2025-07-09	Herabstufung	UBS	Buy → Neutral
2025-01-10	Hochstufung	Bernstein	Mkt Perform → Outperform
2024-12-23	Eingeleitet	Scotiabank	Sector Perform
2024-10-14	Eingeleitet	Redburn Atlantic	Buy
2024-10-01	Eingeleitet	Stephens	Overweight
2024-08-28	Eingeleitet	Wells Fargo	Overweight
2024-06-03	Fortgesetzt	Jefferies	Buy
2024-03-18	Fortgesetzt	Citigroup	Neutral
2024-01-24	Herabstufung	Barclays	Overweight → Equal Weight
2024-01-08	Herabstufung	Bernstein	Outperform → Mkt Perform
2023-12-18	Eingeleitet	HSBC Securities	Buy
2023-12-13	Eingeleitet	Wolfe Research	Outperform
2023-10-26	Herabstufung	KeyBanc Capital Markets	Overweight → Sector Weight
2023-10-25	Hochstufung	Wells Fargo	Underweight → Equal Weight
2023-09-28	Eingeleitet	Bernstein	Outperform
2023-09-06	Fortgesetzt	Citigroup	Buy
2023-07-19	Eingeleitet	Raymond James	Outperform
2023-07-19	Bestätigt	Robert W. Baird	Outperform
2023-07-13	Hochstufung	Credit Suisse	Neutral → Outperform
2023-04-04	Bestätigt	Barclays	Overweight
2022-12-14	Eingeleitet	Deutsche Bank	Buy
2022-12-07	Eingeleitet	RBC Capital Mkts	Outperform
2022-10-27	Herabstufung	The Benchmark Company	Buy → Hold
2022-08-25	Eingeleitet	Credit Suisse	Neutral
2022-04-25	Herabstufung	Wells Fargo	Equal Weight → Underweight
2022-01-26	Fortgesetzt	Barclays	Overweight
2021-10-20	Hochstufung	Citigroup	Neutral → Buy
2021-10-15	Fortgesetzt	Cowen	Outperform
2021-08-05	Fortgesetzt	Credit Suisse	Outperform
2021-07-16	Eingeleitet	The Benchmark Company	Buy
2021-03-18	Hochstufung	KeyBanc Capital Markets	Sector Weight → Overweight
2021-03-03	Eingeleitet	Barclays	Overweight
2021-01-08	Hochstufung	Credit Suisse	Neutral → Outperform
2020-12-16	Herabstufung	Citigroup	Buy → Neutral
2020-12-02	Eingeleitet	Goldman	Buy
2020-11-10	Eingeleitet	KeyBanc Capital Markets	Sector Weight
2020-09-30	Eingeleitet	Atlantic Equities	Overweight
2020-09-14	Eingeleitet	Morgan Stanley	Overweight
2020-08-20	Fortgesetzt	JP Morgan	Overweight
2020-07-15	Hochstufung	Cleveland Research	Neutral → Buy
2020-07-07	Bestätigt	Needham	Buy
2020-04-23	Bestätigt	Needham	Buy
2020-01-31	Bestätigt	Needham	Buy
2020-01-22	Eingeleitet	Credit Suisse	Neutral
2020-01-08	Eingeleitet	Wells Fargo	Equal Weight
2020-01-07	Eingeleitet	Citigroup	Buy
2019-11-15	Eingeleitet	Stifel	Buy
2019-07-25	Bestätigt	Needham	Buy
2019-07-16	Herabstufung	Needham	Strong Buy → Buy
2019-05-30	Eingeleitet	Wolfe Research	Outperform
2019-05-23	Bestätigt	Needham	Strong Buy
2019-04-22	Bestätigt	Needham	Strong Buy
2019-04-16	Bestätigt	BofA/Merrill	Buy

Alle ansehen

Thermo Fisher Scientific Inc Aktie (TMO) Neueste Nachrichten

Jul 28, 2026

Flow Cytometry Diagnostics Market Set to Reach USD 3.5 Billion by 2036 Driven by MRD Testing and Multiparametric Analysis | Sysmex Corporation, Thermo Fisher Scientific Inc. - 24-7 Press Release Newswire

Jul 28, 2026

Jul 27, 2026

Form 144 THERMO FISHER SCIENTIFIC INC. For: 27 July By Investing.com - Investing.com India

Jul 27, 2026

Daily Brief Health Care: Apnimed, Chugai Pharmaceutical, Equifax Inc, Royalty Pharma , Startline, Surgery Partners, Teva Pharmaceutical Sp Adr, Thermo Fisher Scientific Inc and more - Smartkarma

Jul 27, 2026

Thermo Fisher Scientific Inc. stock falls Monday, underperforms market - MarketWatch

Jul 27, 2026

TMO Maintained by Piper Sandler -- Price Target Raised to $600 - GuruFocus

Jul 27, 2026

Thermo Fisher (TMO) insider files to sell 400 common shares valued at $226,000 - Stock Titan

Jul 27, 2026

Piper Sandler Adjusts Price Target on Thermo Fisher Scientific to $600 From $510, Maintains Neutral Rating - marketscreener.com

Jul 27, 2026

Thermo Fisher Scientific Presents End-to-End Diagnostic and Lab Solutions Addressing Unmet Clinical Needs at ADLM 2026 - Yahoo Finance

Jul 27, 2026

Thermo Fisher stock holds on steady earnings base - Ad-hoc-news.de

Jul 27, 2026

THERMO FISHER SCIENTIFIC INC : PIPER SANDLER RAISES TARGET PRICE TO $600 FROM $510 - Bitget

Jul 27, 2026

Jul 25, 2026

Thermo Fisher Scientific (NYSE:TMO) Faces A Margin Test - Kalkine Media

Jul 25, 2026

Thermo Fisher Scientific Q2 up 10% to USD 11.99 billion - Medical Buyer

Jul 25, 2026

Thermo Fisher stock trades steadily as diagnostics and biopharma demand support earnings trajectory - AD HOC NEWS

Jul 25, 2026